| For: | Yang M, Zhang CY. G protein-coupled receptors as potential targets for nonalcoholic fatty liver disease treatment. World J Gastroenterol 2021; 27(8): 677-691 [PMID: 33716447 DOI: 10.3748/wjg.v27.i8.677] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v27/i8/677.htm |
| Number | Citing Articles |
| 1 |
Darya A. Pon’kina, Sergey O. Kuranov, Mariya K. Marenina, Yulia V. Meshkova, Nataliya A. Zhukova, Mikhail V. Khvostov, Olga A. Luzina, Tatiana G. Tolstikova, Nariman F. Salakhutdinov. Bornyl-Containing Derivatives of Benzyloxyphenylpropanoic Acid as FFAR1 Agonists: In Vitro and In Vivo Studies. Pharmaceutics 2023; 15(6) doi: 10.3390/pharmaceutics15061670
|
| 2 |
Jerome Lian, Mohan Patil, Ricky R. Lareu, Marco Falasca. Acute Effects of Cannabinoid Combination Therapies in a Western Diet-Induced Murine Model of Metabolic Liver Disease. International Journal of Molecular Sciences 2026; 27(11) doi: 10.3390/ijms27114872
|
| 3 |
Chunye Zhang, Ming Yang. Targeting T Cell Subtypes for NAFLD and NAFLD-Related HCC Treatment: An Opinion. Frontiers in Medicine 2021; 8 doi: 10.3389/fmed.2021.789859
|
| 4 |
Samar F. Darwish, Sherif S. Abdel Mageed, Abdulla M.A. Mahmoud, Aya A. El-demerdash, Ahmed S. Doghish, Reem K. Azzam, Roudina E. Mohamed, Engy A. Farouk, Mina Noshy, Marwa M. Shakweer, Ola Elazazy. Pinocembrin protects against cisplatin-induced liver injury via modulation of oxidative stress, TAK-1 inflammation, and apoptosis. Toxicology and Applied Pharmacology 2025; 502 doi: 10.1016/j.taap.2025.117433
|
| 5 |
Isabel Cornejo-Pareja, Mohamed Reda Amiar, Luís Ocaña-Wilhelmi, Rocío Soler-Humanes, Isabel Arranz-Salas, Lourdes Garrido-Sánchez, Carolina Gutiérrez-Repiso, Francisco Jose Tinahones. Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism. Journal of Gastroenterology 2024; 59(4) doi: 10.1007/s00535-023-02075-7
|
| 6 |
Ye Li, Yurong Ren, Ning Jia, Xiaoming Zhang, Yuanqing Luo, Jianrong Cao, Yan Yuan, Zitian Wang, Yiting Gong, Xueyuan Zhi. Ginsenoside Rg1 alleviated arsenic-induced liver fibrosis through modulating gut microbiome. Food Bioscience 2025; 71 doi: 10.1016/j.fbio.2025.107402
|
| 7 |
Chun-Ye Zhang, Shuai Liu, Ming Yang. Crosstalk between gut microbiota and COVID-19 impacts pancreatic cancer progression. World Journal of Gastrointestinal Oncology 2022; 14(8): 1456-1468 doi: 10.4251/wjgo.v14.i8.1456
|
| 8 |
Junli Feng, Shitong Wang, Feifei Chen, Jian Zhang, Qingcheng Wang, Lili Jiang, Zejun Wang, Qing Shen. Effects of triglyceride and ethyl ester forms of EPA on hepatic lipid metabolism in mice with non-alcoholic fatty liver disease. Journal of Functional Foods 2024; 116 doi: 10.1016/j.jff.2024.106179
|
| 9 |
Mengmeng Zhang, Xiang Mai, Shanghua Yang, Yuhua Huang, Lina Zhang, Wenbin Ren, Weidong Bai, Xuan Xin, Wenhong Zhao, Lisha Hao. Efficient Hydrolysis of Earthworm Protein and the Lipid-Lowering Mechanism of Peptides in the Hydrolysate. Foods 2025; 14(13) doi: 10.3390/foods14132338
|
| 10 |
Youngmin A. Lee, Scott L. Friedman. Inflammatory and fibrotic mechanisms in NAFLD—Implications for new treatment strategies. Journal of Internal Medicine 2022; 291(1) doi: 10.1111/joim.13380
|
| 11 |
Chunye Zhang, Shuai Liu, Ming Yang. Hepatocellular Carcinoma and Obesity, Type 2 Diabetes Mellitus, Cardiovascular Disease: Causing Factors, Molecular Links, and Treatment Options. Frontiers in Endocrinology 2021; 12 doi: 10.3389/fendo.2021.808526
|
| 12 |
Weiwei Li, Mingjuan Deng, Jiahui Gong, Yichao Hou, Liang Zhao. Bidirectional Regulation of Sodium Acetate on Macrophage Activity and Its Role in Lipid Metabolism of Hepatocytes. International Journal of Molecular Sciences 2023; 24(6) doi: 10.3390/ijms24065536
|
| 13 |
Jiajie Mao, Huijing Bao. The Gut Microbiota-Ovarian Cancer Axis: Mechanisms of Influence and Therapeutic Implications. Technology in Cancer Research & Treatment 2026; 25 doi: 10.1177/15330338261428216
|
| 14 |
Fatema Safri, Russell Pickford, Yikun Xu, William Yang, Romario Nguyen, Lawrence Yuen, Vincent Lam, Christopher Nahm, Tony Pang, Jacob George, Liang Qiao. Integrated Plasma and Tissue Lipid Profiling Demonstrates a Distinctive Metabolic Profile in MAFLD-Associated Non-Cirrhotic Hepatocellular Carcinoma. International Journal of Molecular Sciences 2026; 27(13) doi: 10.3390/ijms27136060
|
| 15 |
Xueping Li, Weijun Cui, Yanfei Cui, Xinling Song, Le Jia, Jianjun Zhang. Stropharia rugoso-annulata acetylated polysaccharides alleviate NAFLD via Nrf2/JNK1/AMPK signaling pathways. International Journal of Biological Macromolecules 2022; 215 doi: 10.1016/j.ijbiomac.2022.06.156
|
| 16 |
Renzhong Lu, Yan Li, Anna Xu, Bridgette King, Ke-He Ruan. Reprogramming Megakaryocytes for Controlled Release of Platelet-like Particles Carrying a Single-Chain Thromboxane A2 Receptor-G-Protein Complex with Therapeutic Potential. Cells 2023; 12(24) doi: 10.3390/cells12242775
|
| 17 |
Zhijun Liu, Yifei Le, Dezhao Lu. PKM2: A novel helmsman of lipid metabolism. Cellular Signalling 2025; 134 doi: 10.1016/j.cellsig.2025.111967
|
| 18 |
Dongjie Wu, Jing Liu, Ziwei Guo, Liang Wang, Ziang Yao, Qingjuan Wu, Yanping Lu, Wenliang Lv. Natural bioactive compounds reprogram bile acid metabolism in MAFLD: Multi-target mechanisms and therapeutic implications. International Immunopharmacology 2025; 157 doi: 10.1016/j.intimp.2025.114708
|
| 19 |
Mathias Haag, Stefan Winter, Aurino M. Kemas, Julia Tevini, Alexandra Feldman, Sebastian K. Eder, Thomas K. Felder, Christian Datz, Bernhard Paulweber, Gerhard Liebisch, Oliver Burk, Volker M. Lauschke, Elmar Aigner, Matthias Schwab. Circulating metabolite signatures indicate differential gut-liver crosstalk in lean and obese MASLD. JCI Insight 2025; 10(8) doi: 10.1172/jci.insight.180943
|
| 20 |
Gina Ryu, Eileen Laurel Yoon, Wankyu Kim, Dae Won Jun. Molecular Clustering of Metabolic Dysfunction-Associated Steatotic Liver Disease Based on Transcriptome Analysis. Diagnostics 2025; 15(3) doi: 10.3390/diagnostics15030342
|
| 21 |
Juanhong Zhang, Yantao Ma, Rong Chang, Rong Wang, Junmin Zhang. The interplay of plant polysaccharide structure, gut microbiota metabolism, and host health: Mechanisms and perspectives. Life Sciences 2026; 395 doi: 10.1016/j.lfs.2026.124383
|
| 22 |
Li-Chiung Lin, Tezz Quon, Susanna Engberg, Amanda E. Mackenzie, Andrew B. Tobin, Graeme Milligan. G Protein-Coupled Receptor GPR35 Suppresses Lipid Accumulation in Hepatocytes. ACS Pharmacology & Translational Science 2021; 4(6) doi: 10.1021/acsptsci.1c00224
|
| 23 |
Chunye Zhang, Ming Yang. Molecular targets regulating endoplasmic reticulum-mitochondria crosstalk for NAFLD treatment. Exploration of Medicine 2021; doi: 10.37349/emed.2021.00066
|
| 24 |
Veronika A. Prikhodko, Natalia N. Bezborodkina, Sergey V. Okovityi. Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates. Biomedicines 2022; 10(2) doi: 10.3390/biomedicines10020274
|
| 25 |
Chunye Zhang, Yi Wang, Takefumi Kimura, Ahmad H. Al-Mrabeh. Editorial: The role of GPCRs in obesity. Frontiers in Endocrinology 2024; 15 doi: 10.3389/fendo.2024.1404969
|
| 26 |
Lena Heinrich, Richell Booijink, Amit Khurana, Ralf Weiskirchen, Ruchi Bansal. Lipoxygenases in chronic liver diseases: current insights and future perspectives. Trends in Pharmacological Sciences 2022; 43(3) doi: 10.1016/j.tips.2021.12.001
|
| 27 |
Chunye Zhang, Yuxiang Sui, Shuai Liu, Ming Yang. Molecular mechanisms of metabolic disease-associated hepatic inflammation in non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Exploration of Digestive Diseases 2023; doi: 10.37349/edd.2023.00029
|
| 28 |
Chunye Zhang, Ming Yang. Current Options and Future Directions for NAFLD and NASH Treatment. International Journal of Molecular Sciences 2021; 22(14) doi: 10.3390/ijms22147571
|
| 29 |
Wesuk Kang, Suhjin Yang, Jiyun Roh, Dabin Choi, Han‐Woong Lee, Jae Hoon Lee, Taesun Park. MOR23 deficiency exacerbates hepatic steatosis in mice. The FASEB Journal 2024; 38(20) doi: 10.1096/fj.202401468RR
|
| 30 |
Chun-Ye Zhang, Shuai Liu, Ming Yang. Treatment of liver fibrosis: Past, current, and future. World Journal of Hepatology 2023; 15(6): 755-774 doi: 10.4254/wjh.v15.i6.755
Abstract(1259) |
Core Tip(1200) |
Full Article(HTML)(11789)
|
Full Article (PDF)-1940K(682)
|
Full Article with Cover (PDF)-4268K(364)
|
Full Article (Word)-1195K(60)
|
Full Article (XML)-339K(208)
|
Audio-303K(20)
|
Peer-Review Report-179K(181)
|
Answering Reviewers-123K(150)
|
Times Cited (84)
|
Total Visits (15551)
|
Open
|
| 31 |
Noorshafadzilah Talib, Nurul Elyani Mohamad, Swee Keong Yeap, Chai Ling Ho, Mas Jaffri Masarudin, Suraini Abd-Aziz, Mira Nadiah Mohd Izham, Muganti Rajah Kumar, Yazmin Hussin, Noorjahan Banu Alitheen. Anti-Diabetic Effect of Lactobacillus Paracasei Isolated from Malaysian Water Kefir Grains. Probiotics and Antimicrobial Proteins 2024; 16(6) doi: 10.1007/s12602-023-10159-2
|
| 32 |
Ting Dong, Guangan Hu, Zhongqi Fan, Huirui Wang, Yinghui Gao, Sisi Wang, Hao Xu, Michael B. Yaffe, Matthew G. Vander Heiden, Guoyue Lv, Jianzhu Chen. Activation of GPR3-β-arrestin2-PKM2 pathway in Kupffer cells stimulates glycolysis and inhibits obesity and liver pathogenesis. Nature Communications 2024; 15(1) doi: 10.1038/s41467-024-45167-5
|
| 33 |
Noorshafadzilah Talib, Nurul Elyani Mohamad, Chai Ling Ho, Mas Jaffri Masarudin, Noorjahan Banu Alitheen. Modulatory Effects of Isolated Lactobacillus paracasei from Malaysian Water Kefir Grains on the Intestinal Barrier and Gut Microbiota in Diabetic Mice. Probiotics and Antimicrobial Proteins 2025; 17(6) doi: 10.1007/s12602-024-10367-4
|
| 34 |
Mengyao Wu, Tak-Ho Lo, Liping Li, Jia Sun, Chujun Deng, Ka-Ying Chan, Xiang Li, Steve Ting-Yuan Yeh, Jimmy Tsz Hang Lee, Pauline Po Yee Lui, Aimin Xu, Chi-Ming Wong. Amelioration of non-alcoholic fatty liver disease by targeting adhesion G protein-coupled receptor F1 (Adgrf1). eLife 2023; 12 doi: 10.7554/eLife.85131
|
| 35 |
Poonam Sahu, Trilochan Satapathy. The Gut-Liver Axis in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Microbiome Interactions and Therapeutic Targets. Probiotics and Antimicrobial Proteins 2026; doi: 10.1007/s12602-026-11050-6
|
| 36 |
Chengyuan Liang, Juan Li, Bin Tian, Lei Tian, Yuzhi Liu, Jingyi Li, Liang Xin, Jun Wang, Chao Fu, Zhenfeng Shi, Juan Xia, Yiting Liang, Kun Wang. Foresight regarding drug candidates acting on the succinate–GPR91 signalling pathway for non-alcoholic steatohepatitis (NASH) treatment. Biomedicine & Pharmacotherapy 2021; 144 doi: 10.1016/j.biopha.2021.112298
|
| 37 |
Chun-Ye Zhang, Shuai Liu, Yu-Xiang Sui, Ming Yang. Roles of short-chain fatty acids in metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis. World Journal of Hepatology 2025; 17(11): 113756 doi: 10.4254/wjh.v17.i11.113756
Abstract(74) |
Core Tip(64) |
Full Article(HTML)(598)
|
Full Article (PDF)-8919K(209)
|
Full Article with Cover (PDF)-9254K(57)
|
Full Article (XML)-301K(43)
|
Audio-183K(24)
|
Peer-Review Report-224K(41)
|
Answering Reviewers-37K(38)
|
Supplementary Material-1524K(31)
|
Times Cited (2)
|
Total Visits (1096)
|
Open
|
| 38 |
Anna Migni, Desirée Bartolini, Giada Marcantonini, Roccaldo Sardella, Mario Rende, Alessia Tognoloni, Maria Rachele Ceccarini, Francesco Galli. Melatonin Repairs the Lipidome of Human Hepatocytes Exposed to Cd and Free Fatty Acid‐Induced Lipotoxicity. Journal of Pineal Research 2025; 77(3) doi: 10.1111/jpi.70047
|
| 39 |
Antwi-Boasiako Oteng, Srinivas Pittala, Andrea Kliewer, Yishu Qiu, Jürgen Wess. Hepatic GRK2 is dispensable for glucose homeostasis and other key metabolic parameters in mice. Molecular Metabolism 2024; 79 doi: 10.1016/j.molmet.2023.101866
|
| 40 |
Yakun Li, Koen C. van Son, Sandra Serna-Salas, Justina C. Wolters, Nienke P. M. Wassenaar, Stan Driessen, Anne Linde Mak, Anne-Marieke van Dijk, Veera A. T. Houttu, Julia J. Witjes, Diona Zwirs, Michail Doukas, Joanne Verheij, Robin P. F. Dullaart, Hans Blokzijl, Adriaan G. Holleboom, Han Moshage. Plasma Extracellular Vesicles Contain Protein Biomarkers for Capturing Stages of Metabolic Dysfunction-Associated Steatotic Liver Disease: A Preliminary Exploratory Study. Biomolecules 2025; 15(11) doi: 10.3390/biom15111596
|
| 41 |
Tamadher Abbas Rafaa, Safa Abbas Khudhair, Zahraa Yassen Mohammed, Ahmed AbdulJabbar Suleiman, Mayank Choubey. Genomic Exploration of Nonalcoholic Fatty Liver Disease: Insights From Gene Expression and Variation in Morbidly Obese Individuals. Journal of Obesity 2025; 2025(1) doi: 10.1155/jobe/9245699
|
| 42 |
Zhuo Huang, Qinyan Yao, Shuang Ma, Jinjie Zhou, Xiaoxuan Wang, Qingguo Meng, Yaxin Liu, Zihan Yu, Xin Chen. The synergistic role of gut microbiota and RNA in metabolic diseases: mechanisms and therapeutic insights. Frontiers in Microbiology 2025; 16 doi: 10.3389/fmicb.2025.1504395
|
| 43 |
Shereen A. El Sobky, Nada El-Ekiaby, Injie O. Fawzy, Amira Khaled Abdelhamid, Heba Attia, Ibrahim H. Fayed, Yasser Badr, Mohammed Emadeldeen, Ahmed Nagy, Mohamed Negm, Mohamed Sherif Negm, Ahmed Moustafa, Mohamed El-Kassas, Mohamed A. Farag, Ramy K. Aziz, Ahmed I. Abdelaziz. Association between the subcellular localization of host proteins and gut microbiome and metabolome in metabolic dysfunction-associated steatotic liver disease: a pilot study. Frontiers in Molecular Biosciences 2026; 13 doi: 10.3389/fmolb.2026.1703547
|
| 44 |
Darya Pon`kina, Sergey Kuranov, Mikhail Khvostov, Nataliya Zhukova, Yulia Meshkova, Mariya Marenina, Olga Luzina, Tatyana Tolstikova, Nariman Salakhutdinov. Hepatoprotective Effect of a New FFAR1 Agonist—N-Alkylated Isobornylamine. Molecules 2023; 28(1) doi: 10.3390/molecules28010396
|
| 45 |
Qingwan Yang, Xin Cai, Shanshan Li, Zhenghua Xiao. Association Between Nonalcoholic Fatty Liver Disease and the Dietary Index for Gut Microbiota: A Cross‐Sectional Study. Food Science & Nutrition 2026; 14(1) doi: 10.1002/fsn3.71451
|